Effects of A2 milk (compared to regular milk) on asthma symptoms, inflammation and exercise performance in athletes with asthma-related conditions

Not Applicable

Completed

• Conditions: Exercise performance and airway health in athletes/physically active adults with asthma/asthma-related conditions or exercise-induced bronchospasm (EIB); Respiratory

• Registration Number: ISRCTN29968077
• Lead Sponsor: niversity of Kent

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-08-22
• Study Completion: 2019-12-31
• Last Update Posted: 20 July 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 9

Inclusion Criteria

1. Ability to consent to the research
2. Prior clinician-based diagnosis of asthma
3. Males and females
4. 18 – 45 years
5. Engage in regular endurance training (at least three times per week)
6. Normal resting Forced Expiratory Volume in One Second (FEV1); defined as greater than 80% of predicted value

Exclusion Criteria

1. Chest infection within the past 4 weeks, or any other illness within the past 2 weeks
2. Fall in FEV1 >50% from baseline following exercise challenge
3. Baseline FEV1 of < 80% of predicted
4. Respiratory conditions (other than asthma/EIB) e.g. COPD
5. Cardiovascular conditions:
5.1. Coronary artery disease
5.2. High blood pressure
5.3. Heart failure
5.4. Diagnosed abnormality of heart rhythm
6. Metabolic diseases:
6.1. Type 1 diabetes
6.2. Type 2 diabetes
6.3. Pre-diabetes
7. Daily use of oral corticosteroids
8. Hospitalisation due to asthma in the six months prior to study commencement
9. Injury or conditions that limit mobility
10. Pregnancy
11. Known allergy or intolerance to milk or dairy
12. Does not regularly consume milk

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<br> All of the following measures will be assessed on 3 separate occasions over the study period - once at at baseline and once after each 2-week period:<br> 1. Eucapnic Voluntary Hyperpnea (EVH) challenge with lung function testing (maximal flow-volume loop method) before and after EVH challenge test. The lung function test will be performed before and at 3, 5, 7, 10, and 15 min post-EVH challenge<br> 2. Urine levels of 9a,11ß-prostaglandin and Clara cell protein (CC16) will be assessed in samples collected before and after (~1 h) EVH challenge by enzyme-linked immunosorbent assay (ELISA) method<br> 3. Exhaled Nitric Oxide levels before and after (1 h) EVH challenge using a exhaled breath gas analyser<br>